🔥Telegram İfşa

Seth M. Pollack joins #SARCTalk to share his insights on #clinicaltrials, #research, and advice for younger #researchers. You don't want to miss this episode, listen now! open.spotify.com/episode/36b31P… #sarcoma #SARCTrials #podcast

Seth M. Pollack joins #SARCTalk to share his insights on #clinicaltrials, #research, and advice for younger #researchers. You don't want to miss this episode, listen now! open.spotify.com/episode/36b31P… #sarcoma #SARCTrials #podcast

Thanks to William Gradishar, MD and elson rothschild for inviting me to deliver a Grand Rounds presentation this morning to the team of physicians at the Lurie Cancer Center & Hematology/Oncology Lurie Cancer Center, and thanks to Seth M. Pollack for the introduction. A great chance to explore

Important @luriecancer clinical trial led by the director of our translational research program Daniela Matei on endometrial cancer, just published in JCO.

Cancer survivors are growing in number. In the US, nearly half of survivors have lived 10 or more years after diagnosis, while 19% have lived 20 or more years. The prevalence of long-term survivors is expected to increase through 2040. go.nih.gov/rOUbZJD #CancerSurvivorship

Northwestern sarcoma holiday party 2024!!!!!! Great party for sarcoma research and clinical teams. Thanks to Pablo Penaloza lab and Jenn Wu’s lab (we got r01’s with both in 2024) Come work with us! My lab is hiring!! Also we are hiring another sarcoma med onc!! Join us!!

Dr. Pedro Antonio Hermida de Viveiros will discuss the phase 2 trial of zanzalintinib for leiomyosarcoma patients at Northwestern Medicine in a free webinar 7 pm EST Feb. 12. Register here: us02web.zoom.us/meeting/regist…. This is presented by LMSDR.org & open to everyone.

We are looking for another #sarcoma Medical Oncologist to join our team in downtown Chicago!! Graduating fellows: you are interested in an academic position in Chicago, we can train you up on the sarcoma part of the job! job is now posted: facultyrecruiting.northwestern.edu

Love OncLive.com Breelyn Wilky, MD 🎗 #GIST : onclive.com/insights/my-tr…

Watch Breelyn Wilky, MD 🎗, of CU Cancer Center, Jason Sicklick of UC San Diego and Seth M. Pollack of Northwestern Feinberg School of Medicine discuss the biological mechanisms of resistance in GIST, differentiating between primary and secondary resistance. Watch the full discussion here: hubs.li/Q03nKB8F0

#ASCO25 Today at 11:30 AM - Nadeem Bilani, MD, of Lurie Cancer Center will present a clinical and genomic landscape analysis of GI stromal tumors during the Sarcoma Rapid Oral Abstract Session. Hall S504. Abstract #11512. Don't miss it! Nadeem Bilani, MD #GIST

Congratulations to Nadeem Bilani, MD, Nadeem Bilani, MD, on receiving a 2025 Merit Award from ASCO’s Conquer Cancer, the ASCO Foundation in recognition of your work! Seth M. Pollack Northwestern Feinberg School of Medicine NU Internal Medicine

Join us in person Lurie Cancer Center tomorrow, Fri. July 11, for our 2025 Oncology Review — a comprehensive summary of key research findings and emerging data in clinical care, presented by our experts. View the details & agenda and register now: cancer.northwestern.edu/events/profess… #CME

#ClinicalTrial EA7222, led by Seth M. Pollack of Lurie Cancer Center, is a randomized phase 3 trial of doxorubicin alone or in combination w/ pembrolizumab for patients w/ advanced soft tissue #sarcoma & related poorly differentiated sarcomas that are unresectable. bit.ly/EA7222

.Seth M. Pollack of Lurie Cancer Center is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: Sarcoma Foundation of America

.Seth M. Pollack of Lurie Cancer Center is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: Sarcoma Foundation of America

New podcast episode with Prof. Ian Judson, a true pioneer in sarcoma oncology! Prof. Judson reflects on his decades of experience — the challenges of treating ultra-rare cancers, the breakthroughs that gave hope, and the importance of teamwork! #CTOS #Sarcoma #GIST #podcast

Excited to be on a #Sarcoma panel with Seth Pollock Seth M. Pollack Dan Olson Bruce Brockstein at the BGT Biomarkers, Genes and Targets Conference in #Chicago chadi nabhan MD, MBA, FACP precisca.com/hubfs/Events/C…

We are looking for another #sarcoma medical oncologist!!!! Please reach out to me if you or some one you know is interested!!!!

🚨Historical presentation at #CTOS2025 ChonDRAgon - first positive randomised trial in chondrosarcoma 🔹Ozekibart vs placebo 🔹 mPFS 5.52 vs 2.66 months 🔹 HR 0.479; p<0.0001 🔹 a manageable safety profile - most common TRAE: fatigue, diarrhea, and nausea